Israel - English - Ministry of Health

novartis israel ltd - omalizumab - powder and solvent for solution for injection - omalizumab 150 mg/dose - omalizumab - omalizumab - allergic asthma xolair is indicated for patients 6 to 12 years of age with severe persistent asthma and for patients 12 years of age and older with moderate to severe persistent asthma, who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. limitations of use: xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. xolair is not indicated for the treatment of other allergic conditions.chronic rhinosinusitis with nasal polyps (crswnp) xolair is indicated as an add-on therapy with intranasal corticosteroids (inc) for the treatment of adults (18 years and above) with severe crswnp for whom therapy with inc does not provide adequate disease control.chronic spontaneous urticaria (csu) xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to h1 antihistamine treatment.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, powder, lyophilized, for solution - 150mg - omalizumab 150mg

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, powder, lyophilized, for solution - 75mg - omalizumab 75mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - omalizumab - solution for injection - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - omalizumab - solution for injection - 150mg/1ml

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, solution - omalizumab 150 mg/1.0 ml

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - omalizumab - injection, solution - omalizumab 75mg/0.5ml

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - drugs for obstructive airway diseases, - allergic asthmaxolair is indicated in adults, adolescents and children (6 to

Canada - English - Health Canada

novartis pharmaceuticals canada inc - omalizumab - powder for solution - 150mg - omalizumab 150mg - respiratory agents, miscellaneous

Canada - English - Health Canada

novartis pharmaceuticals canada inc - omalizumab - solution - 75mg - omalizumab 75mg - respiratory agents, miscellaneous